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Abstract: The urinary bladder has two functions: urine storage and voiding. Clinically, two
major categories of lower urinary tract symptoms can be deﬁned: storage symptoms such as
incontinence and urgency, and voiding symptoms such as feeling of incomplete bladder
emptying and slow urinary stream. Urgency to void with or without incontinence is called
overactive bladder (OAB). Slow urinary stream, hesitancy, and straining to void with the
feeling of incomplete bladder emptying are often called underactive bladder (UAB). The
underlying causes of OAB or UAB can be either non-neurogenic (also referred to as
idiopathic) and neurogenic, for example due to spinal cord injury or multiple sclerosis.
OAB and UAB can be treated conservatively by lifestyle intervention or medication. In
the case that conservative treatment does not provide sufﬁcient beneﬁt, electrical stimulation
can be used. Sacral neurostimulation or neuromodulation (SNM) is offered as a third-line
therapy to patients with non-neurogenic OAB or UAB. In SNM, the third or fourth sacral
nerve root is stimulated and after a test period, a neuromodulator is implanted in the buttock.
Until recently only a non-rechargeable neuromodulator was approved for clinical use.
However, nowadays, a rechargeable sacral neuromodulator is also on the market, with
similar safety and effectiveness to the non-rechargeable SNM system. The rechargeable
device was approved for full body 1.5T and 3T MRI in Europe in February 2019.
Regarding neurogenic lower urinary tract dysfunction, electrical stimulation only seems to
beneﬁt a selected group of patients.
Keywords: lower urinary tract symptoms, neurogenic bladder, electrical stimulation,
neuromodulation, sacral neuromodulation, tibial nerve stimulation
Introduction
The urinary bladder has two functions: urine storage and voiding. Patients experience
lower urinary tract symptoms (LUTS) in the case of storage and/or voiding dysfunc-
tion. These symptoms can be divided into two categories: storage symptoms and (post-)
voiding symptoms. Storage symptoms are: increased daytime frequency, nocturia,
urgency, urgency urinary incontinence, stress urinary incontinence, and mixed urinary
incontinence. Voiding symptoms are: slow stream, intermittency, hesitancy, straining to
void, feeling of incomplete bladder emptying, and post-micturition dribble. Storage
symptoms are the most prevalent and the most bothersome for patients.1,2 Urgency to
void with or without incontinence is called overactive bladder (OAB) and has a
prevalence of 11.8%.1 Slow urinary stream, hesitancy, and straining to void with the
feeling of incomplete bladder emptying are often called underactive bladder (UAB).3
In our view, UAB with signiﬁcant post void residue (PVR), which necessitates regular
drainage of the bladder, is clinically much more important than UAB without
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signiﬁcant PVR. The underlying causes of OAB and UAB
can be grouped into non-neurogenic (also referred to as
idiopathic) and neurogenic causes. Neurogenic causes are,
for example, spinal cord injury, Parkinsonism, multiple
sclerosis, and spina biﬁda. The division between non-neuro-
genic and neurogenic causes is important for the choice of
treatment.
Table 1 gives an overview of the treatment modalities for
OABandUAB. Patientswith non-neurogenicOABorUABare
initially treated with lifestyle intervention, physical therapy, or
biofeedback. Pharmacotherapy is offered as a second-line ther-
apy. When these treatment modalities fail, sacral neuromodula-
tion (SNM) or intradetrusor botulinum toxin A
(onabotulinumtoxinA or abotulinumtoxinA) injections can be
offered. Urinary incontinence due to neurogenic OAB or UAB,
on the other hand, is initially treated with pharmacotherapy.
Secondly, intradetrusor botulinum toxin A injections can be
offered.When botulinum toxin A injections fail in the treatment
of neurogenic OAB, surgical interventions such as bladder
augmentation and urinary diversion can be suggested. UAB
due to neurogenic lower urinary tract dysfunction resulting in
signiﬁcant PVR is treatedwith clean intermittent catheterization.
Secondly, an indwelling catheter may be given or a surgical
intervention known as sphincterotomy can be performed.
Electrical stimulation is considered an option only in selected
cases of neurogenic OAB or UAB. This review provides an
overviewof the latest research regarding electrical stimulation in
the treatment of non-neurogenic and neurogenic OAB
and UAB.
Firstly, a summary of clinically approved modes of
electrical stimulation in the treatment of non-neurogenic
OAB and UAB is provided. In the second section, the non-
approved modes of electrical stimulation in the treatment
of OAB and UAB are discussed. In the ﬁnal section, the
possible modes of electrical stimulation in the treatment of
neurogenic OAB and UAB are summarized.
Clinically approved modes of
electrical stimulation in the
treatment of non-neurogenic OAB
and UAB
In this section, SNM with non-rechargeable and recharge-
able systems is discussed, after which posterior tibial
nerve stimulation is addressed. In Table 2, the chronology
of introduction and approval of these devices is given.
Sacral neuromodulation
SNM may improve both the storage and voiding function
of the bladder. It is therefore used both in patients with
OAB syndrome presenting with symptoms such as
urgency urinary incontinence and urgency-frequency as
well as in patients with UAB. An SNM system consists
Table 1 Treatment options for overactive and underactive bladder
Type of
dysfunction
Overactive bladder Underactive bladder
Symptoms Treatment
(idiopathic)
Treatment
(neurogenic)
Symptoms Treatment
(idiopathic)
Treatment
(neurogenic)
Storage Urgency
Urgency urinary
incontinence Increased
daytime frequency
Nocturia
Lifestyle
intervention
Pharmacotherapy
SNM
Intradetrusor
botulinum toxin A
Surgical
interventions
Pharmacotherapy
Intradetrusor
botulinum toxin
Surgical intervention
– – –
Voiding – – – Slow stream
Hesitancy
Straining to
void
Feeling of
incomplete
bladder
emptying
Pharmacotherapy
Clean
intermittent
catheterization
Indwelling
catheter
Surgical
intervention
Pharmacotherapy
Clean
intermittent
catheterization
Indwelling
catheter
Surgical
intervention
Abbreviaton: SNM, sacral neuromodulation.
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of a lead with four electrodes stimulating the S3 or S4
sacral nerve root. The lead is connected to a subcutaneous
pulse generator. The lead is usually placed on one side in
one of the sacral foramina. It is thought that SNM acti-
vates afferent pathways which modulate forebrain struc-
tures involved in awareness and alertness.4,5 This
mechanism is probably similar in, for example, tibial
nerve stimulation and pudendal nerve stimulation.
However, SNM recruits 1000-times more axons than sti-
mulation of a single nerve.
Non-rechargeable SNM systems
Until recently, the only commercially available devices
were the voltage-driven InterStim and InterStim II
(Medtronic, Minneapolis, USA). The InterStim II is a
smaller, lighter version of the InterStim device.6 It weighs
22 g and is 51 by 44 by 7.7 mm in size. The pulse
generator can deliver pulses at a rate of 2.1–130 Hz with
a pulse width of 60–450 µs, at a maximum amplitude of
8.5 V. A signiﬁcant improvement of the initially developed
lead was introduced in 2002. This so-called tined lead
eliminated the need to ﬁxate the lead to the surrounding
tissue since the tines ensure that the lead is anchored
properly. This made the implant procedure faster and less
invasive. Due to battery depletion patients require revision
surgeries to replace the battery. Increasing battery life has
been a goal for some time. There is a trade-off between
size and battery longevity, a smaller device has a shorter
lifespan. The InterStim and the smaller InterStim II have a
battery life of approximately 5.5–9.2 and 2.9–5.4 years,
respectively, depending on the parameter settings.7 In
practice, the pulse width ranges from 180 to 220 ms, the
frequency lies between 10 and 20 Hz and the amplitude is
smaller than 3.5 V.8 No differences concerning efﬁcacy
have been observed between continuous and cyclic
stimulation.9
The effectiveness of SNM in women with refractory
idiopathic urgency urinary incontinence was evaluated
after 5 years follow-up.10 Eighty per cent of the patients
still used the SNM system after 5 years. At 1-month
follow-up, 87% had a 50% or higher reduction of incon-
tinence episodes or daily pad use. This number decreased
to 62% at 5 years. In 15% of the patients, complete con-
tinence was achieved throughout the follow-up period. In a
clinical study of 27 patients with non-obstructive urinary
retention, 83% of the patients had a 50% or higher reduc-
tion of symptoms at a median follow-up duration of 5.7
(±3.2) years.11 However, 42% of the patients required one
or more surgical revisions. In a randomized trial compar-
ing intradetrusor onabotulinumtoxinA injections of 200 U
to SNM in patients with urgency urinary incontinence
refractory to lifestyle intervention and pharmacotherapy
options, a signiﬁcant decrease in symptoms was reported
in both groups.12,13 However, the onabotulinumtoxinA
group had a greater reduction urgency urinary inconti-
nence episodes during the ﬁrst 6 months of follow-up,
urgency urinary incontinence episodes decreased with 3.9
a day compared to a decrease of 3.3 in the SNM group.
This signiﬁcant difference in symptom decrease is of
unknown clinical importance. The extent to which these
results can be related to clinical practice is limited by the
fact that the applied dosage of 200 U onabotulinumtoxinA
is not approved by the FDA or CE. The effects of the 200
U onabotulinumtoxinA extend longer than the FDA
approved dose of 100 U for idiopathic OAB.14 However,
the 200 U dose is associated with more complications than
the 100 U dose. In clinical practice, after repeat
onabotulinumtoxinA injections of 100 U patients often
ask for a more deﬁnitive solution, and SNM is offered to
these patients.
Rechargeable SNM systems
A rechargeable current-driven SNM system presumably
has a longer life span than non-rechargeable devices, last-
ing up to 15 years, leading to fewer replacement surgeries.
The Axonics r-SNM is a rechargeable sacral neuromodu-
lator (Figure 1).15 This device is smaller in size compared
to non-rechargeable devices: it is 5 cc in volume whereas
Table 2 Introduction and approval of sacral neuromodulation and tibial nerve stimulation
Modality Subtype First introduced FDA approved CE mark Longevity
SNM Non-rechargeable 1979 1997 1994 3–5 years
Rechargeable 2016 – 2016 15 years
Tibial nerve stimulation Non-implantable 1983 2005 2005 –
Implantable 2010 2018 (approval for study design) 2016 –
Abbreviatons: SNM, sacral neuromodulation; FDA, Food and Drug Administration (USA); CE, Conformité Européenne (Europe).
Dovepress Coolen et al
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the InterStim II is 14 cc in volume. At the last follow-up
visit in a clinical study, the average amplitude was 1.7
(±1.1) mA, the frequency was 14.3 (±1.6) Hz, the pulse
width was 210.6 (±11.6) microseconds, and the impedance
was 1201 (±214) ohms.16 These parameter settings are
comparable to those of the InterStim system. The
Axonics r-SNM device requires frequent recharging. This
is done transcutaneously and takes approximately 1 hr. In a
clinical study, the recharge interval for most patients
(69%) was 14 days or more.16 Almost all patients were
able to recharge their device 3 months after implantation.
Rechargeable systems are probably less costly than non-
rechargeable systems, due to the fact that device replace-
ment is an important cost factor in the total costs of SNM
therapy.17 The Axonics r-SNM has been shown to be
effective and improves quality of life in patients with
OAB during a follow-up period of 1 year.18,19 The possi-
ble advantage of a current driven system over a voltage
drive neuromodulator is that fewer adjustments in the out-
patient clinic are necessary due to the fact that the system
gives a constant current to the nerve ﬁbers independent of
the resistance of the surrounding tissue. Furthermore, in
February 2019, the system was approved for full body
1.5T and 3T MRI (CE mark) in Europe, being the ﬁrst
implantable SNM system that was granted this approval.
Posterior tibial nerve stimulation
This technique involves one-sided stimulation of the pos-
terior tibial nerve, 5 cm above the medial malleolus of the
ankle. Stimulation can be carried out transcutaneously
with a surface electrode, or percutaneously by placing a
needle through the skin. The signal is retrogradely con-
ducted through nerve ﬁbers originating from L4 to S3.
Percutaneous tibial nerve stimulation has been FDA
approved and has a CE mark for the treatment of OAB.
Percutaneous and transcutaneous stimulation are car-
ried out once or twice a week for 30 mins with a non-
implantable device. A disadvantage of these methods is
the fact that patients need weekly hospital visits. A com-
parison between the transcutaneous and the percutaneous
methods has been made for patients with OAB.20
Transcutaneous stimulation consisted of sessions of 30
mins once a week for 12 weeks using biphasic square
waves at a 20 Hz frequency with 200 cycles per second.
Percutaneous stimulation parameters were the same. Both
methods decreased voiding frequency and gave a similar
improvement in the quality of life. The number of axons
that are activated by tibial nerve stimulation is a 1000-fold
less than the number activated by SNM, so tibial nerve
stimulation is probably less effective than SNM.4 In addi-
tion, SNM provides continuous stimulation whereas tibial
nerve stimulation is carried out once a week initially and
once every 2 weeks at a later stage.
The BlueWind RENOVA (BlueWind Medical,
Herzliya, Israel) is a relatively new implantable tibial
nerve stimulator and has a volume of 0.3 cc and a diameter
of 3.4 mm.21 Implantation of the device is done under
local or general anesthesia. Patients themselves apply sti-
mulation with an external control unit worn around the
ankle. In a study by Heesakkers et al, OAB patients
stimulated during the ﬁrst 3 months for 30 mins a day, 6
days a week and, thereafter, during 3 days a week for 3
months.22 Stimulation was performed at a frequency of 40
Hz with a pulse width up to 800 µs at a maximum
amplitude of 9 mA. During follow-up, 70.6% of the
patients experienced a 50% or higher reduction of symp-
toms and quality of life signiﬁcantly improved. Recently,
the coin-sized implantable tibial nerve stimulator eCoin
(Valencia Technologies Corporation, Valencia, USA) was
tested in 46 patients with refractory OAB symptoms dur-
ing a follow-up period of 6 months.23 The eCoin is a
leadless implant that has a diameter of 23 mm and a
thickness of 2.4 mm and comes with an external controller.
The devices give a constant current pulse of 20 Hz with a
pulse width of 0.2 ms with an amplitude of 0.5–15 mA.
The amplitude is adjustable by the external controller.
During 12 weeks, 30 mins simulation sessions were eli-
cited by the device every 2 days; thereafter, simulation
Figure 1 Anterior ﬂuoroscopy of an implanted rechargeable SNM. The arrowhead
points to the four electrodes.
Abbreviaton: SNM, sacral neuromodulation.
Coolen et al Dovepress
submit your manuscript | www.dovepress.com
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sessions were carried out every 15 days. The eCoin is
implanted under local anesthesia. There was a 71% med-
ian reduction of urgency urinary incontinence episodes
during follow-up with 4.2 urgency urinary incontinence
episodes per day at baseline and 1.5 at 6 months. One
serious adverse event was reported related to the implanta-
tion procedure. After all, this device seems promising,
however, there are no data of the possible longevity of
this battery-powered non-rechargeable device.
Non-approved modes of electrical
stimulation in the treatment of non-
neurogenic OAB and UAB
Intravesical stimulation
During intravesical stimulation, a neutral electrode is
placed on the skin and an active electrode is placed trans-
urethrally into the bladder. In a clinical study of 17
patients with OAB, intravesical stimulation was given
twice a week for 4 weeks.24 Twelve weeks after the start
of treatment, voiding frequency was signiﬁcantly reduced
and health-related quality of life had signiﬁcantly
improved compared to baseline. However, urgency urinary
incontinence did not signiﬁcantly change. In a retrospec-
tive study of 89 patients with UAB stimulation sessions
were performed 5 days a week for 30 mins until bladder
function was normal or no further improvement was
achieved.25 Stimulation parameters were as follows: 1–30
mA pulse amplitude, 10–25 Hz pulse frequency, and a
200–800 µs pulse width. On average, 27 (±25) treatment
sessions were performed on each patient, with a range of
5–181. Intravesical stimulation signiﬁcantly decreased
retention, 47% had a more than 40% reduction of PVR.
Also, voiding efﬁciency signiﬁcantly increased. However,
research on long-term effects of intravesical stimulation is
lacking, and comparative research on stimulation settings
is limited.
Pudendal nerve stimulation
The pudendal nerve is usually accessed percutaneously
through a posterior approach during a surgery under general
anesthesia. A needle is placed medial to the ischial tuber-
osity where after the lead is placed. Radiographs are made
to assess the lead position. Animal studies have shown
various effects of pudendal nerve stimulation on bladder
function. Bladder capacity was shown to increase by sen-
sory pudendal nerve stimulation in an OAB rat model.26
Furthermore, animal studies have revealed alterations in the
expression of proteins as a consequence of electrical stimu-
lation. Jiang et al, studied a rat model with stress urinary
incontinence and found that stimulation promotes neuronal
regeneration, possibly through upregulation of brain-
derived neurotrophic factor in motorneurons.27 In a clinical
study by Peters et al, a comparison was made between SNM
and pudendal nerve stimulation to treat bladder dysfunction
in 37 patients with OAB symptoms and three patients with
urinary retention.28 They reported an overall reduction in
symptoms of 63% with pudendal nerve stimulation and
46% with SNM. Patients reported greater improvement of
pelvic pain, urgency, frequency, and bowel dysfunction
with pudendal nerve stimulation as opposed to SNM.
However, the different effects on voiding frequency did
not appear from voiding diaries.
Saphenous nerve stimulation
The saphenous nerve is a sensory nerve innervating the
medial part of the skin between the ankle and the knee. In
a study regarding 15 healthy participants, electrical stimu-
lation of the saphenous nerve was performed with two
surface electrodes.29 Stimulation was carried out during
1-hr session at a frequency of 20 Hz with a pulse width of
200 µs. The nerve was activated when the amplitude of
stimulation was 25.7 (±7.4) mA and the highest tolerable
level of activation was at an amplitude of 47.7 (±9.3) mA.
This result indicates that transcutaneous stimulation can
achieve saphenous nerve activation at a tolerable level.
However, this study did not consider outcome measures
related to bladder function.
In a pilot study in 18 female patients with idiopathic
OAB, the saphenous nerve was stimulated percutaneously
once a week during 3 months.30 Stimulation sessions
lasted 30 mins. Stimulus pulses were 200 µs wide and
were applied at a frequency of 20 Hz. The amplitude was
set at the highest tolerable level to achieve the maximum
therapeutic effect. After 3 months signiﬁcant decreases in
urgency, urgency urinary incontinence and nocturia were
reported and a signiﬁcant increase in the overall health-
related quality of life was observed. Frequency, however,
was not signiﬁcantly different compared to baseline.
Transcutaneous electrical nerve
stimulation
Transcutaneous electrical nerve stimulation (TENS) is car-
ried out with surface electrodes, and therefore, provides a
non-invasive alternative to other stimulation modalities.
Dovepress Coolen et al
Medical Devices: Evidence and Research 2019:12 submit your manuscript | www.dovepress.com
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Above we described TENS of the tibial nerve. Other sites
suitable for TENS include the suprapubic, sacral, penile/
clitoral, vaginal, and rectal areas. Effectiveness of TENS
has been demonstrated in patients with idiopathic bladder
dysfunction.31 Areas of stimulation were the dermatomes
of S2 and S3 and the thigh area. Stimulation frequency
was 20–50 Hz, and the pulse width was 200 µs.
Stimulation was carried out daily during 2–6 weeks.
Only short-term clinical improvement was shown. There
are no data on long-term efﬁcacy.
Electrical stimulation in the
treatment of neurogenic OAB and
UAB
Electrical stimulation in the treatment of neurogenic lower
urinary tract dysfunction is not approved by the FDA and
has no CE mark.
Sacral neuromodulation
The results regarding the effectiveness of SNM in patients
with neurogenic OAB and UAB are conﬂicting. It seems
that SNM cannot reliably suppress detrusor overactivity
due to neurogenic causes.32 The results in patients with
spinal cord injury are inconclusive.33 In a study in patients
with multiple sclerosis, however, voided volume signiﬁ-
cantly increased, PVR signiﬁcantly decreased, voiding
frequency signiﬁcantly decreased, and incontinence signif-
icantly decreased during a follow-up period of 3 years.34
The effects of SNM seem to be lost after time which could
be a consequence of neurological deterioration due to the
underlying disease.
Brindley stimulator
The Brindley stimulator (Finetech Medical Ltd., Welwyn
Garden City, UK) is meant to restore bladder emptying in
patients with a spinal cord lesion.35 The implant procedure
consists of the bilateral placement of electrodes over the
ventral roots of S2–S4, combined with a rhizotomy of the
dorsal roots of these nerves. The dorsal rhizotomy is
necessary to abolish reﬂexive contraction of the bladder.
However, sensory information conveyed by the dorsal
roots is consequently also abolished. For that reason, the
Brindley stimulator is solely used in patients with a com-
plete spinal cord lesion. The electrodes, placed extradu-
rally or intrathecally, are connected to an internal receiver
placed subcutaneously below the ribs in the abdomen. The
patient can void by placing an external transmitter block,
which is connected to a digital controller, over the skin
where the internal receiver is situated. Stimulation para-
meters can be adjusted within certain limits: the frequency
ranges from 2 to 53 Hz, the amplitude ranges from 10 to
40 V, and the pulse width ranges from 0 to 720 µs. In
addition to bladder emptying, defecation and erection can
be induced depending on parameter settings. In patients
with complete spinal cord injury and detrusor overactivity,
a 68% reduction of urinary tract infections, a 54%
improvement in social life, and a 54% improvement in
continence has been reported.36 The effectiveness of the
procedure has been reported in several studies with a
maximum follow-up of 12 years.37 Despite the beneﬁcial
effects, the Brindley stimulator is currently no longer
being implanted.
Pudendal nerve stimulation
In patients with neurogenic lower urinary tract dysfunc-
tion, the overall symptom score was reduced by 52% post
pudendal nerve stimulation.38 In this study, pudendal nerve
stimulation was carried out during 12 sessions spread out
over 4 consecutive weeks. Electrical stimulation was con-
ducted with two pairs of needles (located 1 cm bilateral to
the sacrococcygeal joint and 1 cm bilateral to the tip of the
coccyx) at a frequency of 2.5 Hz with an amplitude of 25–
35 mA for 45 mins. Filling problems, including inconti-
nence, and voiding problems were markedly reduced. The
long-term efﬁcacy of pudendal nerve stimulation in the
treatment of neurogenic lower urinary tract dysfunction is
yet to be studied.
Tibial nerve stimulation
Tibial nerve stimulation provides a non-invasive (transcu-
taneous) or minimally invasive (percutaneous) option in the
treatment of neurogenic lower urinary tract dysfunction.
Multiple clinical studies have been conducted in patients
with neurogenic lower urinary tract dysfunction. These
studies indicate that tibial nerve stimulation might be effec-
tive and safe for these patients.39 In a study conducted in
multiple sclerosis patients with an OAB, stimulation was
applied once a week for 12 weeks.40 Patients who
responded well continued the treatment, at ﬁrst, once
every 2 weeks during 3 months. Subsequently, the interval
was enlarged to once every 3 weeks during 3 months fol-
lowed by once every 4 weeks during 3 months. Stimulation
was carried out percutaneously with a frequency of 20 Hz
and a pulse width of 200 µs. The amplitude was set at the
maximum tolerable level for each patient. At the 1-year
Coolen et al Dovepress
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endpoint, symptoms were signiﬁcantly improved. Although
promising, the study is a retrospective non-controlled study.
In another study, conducted in patients with Parkinson’s
Disease (percutaneous stimulation weekly during 12
weeks, 200 Hz, 200 s), LUTS and urodynamic parameters
improved signiﬁcantly.41
Transcutaneous electrical nerve
stimulation
A systematic review of the literature regarding TENS for neuro-
genic bladder dysfunction was performed by Gross et al, in
2016.42 Suprapubic or sacral stimulation in the identiﬁed studies
was performed at a frequency of 20, 50, or 75 Hz with a pulse
width of 200 µs at an amplitude of 16 or 20 mA or at a
comfortable sensation. The duration of stimulation sessions in
the different studies was 15, 30, and 180 mins per day for a
duration of 30–720 days. Clitoral/penile stimulation was carried
out at a frequency of 5–25Hzwith a pulsewidth of 200–1500 µs
and an amplitude which was the maximal tolerable or at 1.5 or 2
times the level at which certain reﬂexes were elicited. The dura-
tion of stimulation ranged from20mins to less than 2 hrs per day
during 1–84 days. Vaginal/rectal stimulation was carried out at a
frequency of 8 or 10Hz, with a pulse width of 400 or 450 µs, for
30 or 40mins a day during 63 or 84 days.OneRCT, inwhich the
sacral area was stimulated, reported a signiﬁcant difference
between the treatment and control group regarding leaks per
day during treatment.43 Gross et al, concluded that TENS has
potential, though there is a need for more reliable data.42
Transcranial magnetic stimulation (TMS)
The effects of repetitive TMS on LUTS have been investigated
in patients with Parkinson Disease, multiple sclerosis, and
incomplete spinal cord injury. Eight patients with Parkinson
Disease and urinary symptoms such as urgency and increased
frequency received inhibitory TMS over the motor cortex for 2
weeks at 1 Hz.44 Two weeks after stimulation ended symptoms
signiﬁcantly reduced compared to baseline. Two weeks later,
symptoms returned to baseline levels. Ten multiple sclerosis
patients received excitatory TMS over the motor cortex for 2
weeks at 5 Hz.45 Six patients suffered detrusor underactivity,
three patients had detrusor overactivity, and one patient had a
combination of both. Urodynamic evaluation was performed 3
days after completion of the 2-week TMS treatment. Nine
patients reported improvement of voiding symptoms, but there
was no improvement of storage symptoms. These subjective
outcomes measures corresponded with the urodynamic para-
meters. Thus, this stimulation protocolmight only be effective in
patients with UAB. In 12 out of 23 patients with incomplete
spinal cord injury an neurogenic bladder symptoms, excitatory
TMSover themotor cortex 20ms before transcutaneous puden-
dal nerve stimulation, facilitated the pudendal anal reﬂex, indi-
cating a possible effect on the urethral sphincter.46 However, no
direct measures related to bladder function were investigated. In
conclusion, TMS has shown positive effects on bladder symp-
toms in the short term in selected groups of patients.
Conclusions and future perspectives
We have discussed multiple electrical stimulation modal-
ities and the effects on bladder function. Stimulation para-
meters (Table 3) vary between the different modalities. The
optimal settings depend on effectiveness and the highest
tolerable level for each patient. Comparative research on
parameter settings for each modality is lacking. Regarding
the effectiveness of SNM, SNM with a non-rechargeable
device has been shown to be an effective treatment option
Table 3 Stimulation parameters of electrical stimulation modalities for bladder dysfunction
Modality Amplitude Frequency Pulse width
SNM 1.7 mA 14.3 Hz 210.6 µs
PTNS 9 mA, 0.5–15 mA 20 Hz, 40 Hz µs 200, 800 µs
Intravesical stimulation 1–30 mA 5–50 Hz 200–800 µs
Pudendal nerve stimulation 25–35 mA 2.5 Hz –
Saphenous nerve stimulation 47.7 mA 20 Hz 200 µs
TENS 16 mA, 20 mA 5–75 Hz 200–1500 µs
Brindley 10–40 V 2–53 Hz 0–720 µs
TMS – 1 Hz, 5 Hz –
Abbreviatons: SNM, sacral neuromodulation; PTNS, percutaneous tibial nerve stimulation; TENS, transcutaneous electrical nerve stimulation; TMS,
transcranial magnetic stimulation.
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for idiopathic OAB and UAB. However, nowadays also a
rechargeable sacral neuromodulator is on the market with
similar safety and effectiveness as the non-rechargeable
SNM system. The rechargeable device has been approved
for full body 1.5T and 3T MRI in Europe. Tibial nerve
stimulation is a less invasive but also less effective alter-
native. Regarding the rechargeable SNM device, only short-
term efﬁcacy has been reported. There is a need for larger
studies with a longer duration of follow-up to study efﬁcacy
and to optimize the conﬁguration of the devices. Regarding
neurogenic lower urinary tract dysfunction, electrical sti-
mulation seems to beneﬁt a selected group of patients only.
Disclosure
The authors report no conﬂicts of interest in this work.
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